Texas Retina Associates | Arlington, TX
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will evaluate the long-term safety and tolerability of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in patients with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomized in WR42221.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Substudy
Inclusion Criteria
Patients must meet the following ocular criteria for the study eye for substudy entry:
Overall decrease in nAMD disease activity detected on SD-OCT AND Stable or improved best-corrected visual acuity (BCVA)
Exclusion Criteria
Prior Ocular Treatments Study Eye
Either Eye
CNV Lesion Charateristics Study Eye
Either Eye
Concurrent Ocular Conditions Study Eye
Either Eye
Concurrent Systemic Conditions
Primary purpose
Allocation
Interventional model
Masking
1,000 participants in 7 patient groups
Loading...
Central trial contact
Reference Study ID Number: GR40549 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal